Director Imran Mir acquires 2,083,334 shares of RANI at $0.60 for $1,260,417.07; company unprofitable with $-6,692,000 net loss.
Director Imran Mir purchased 2,083,334 shares at $0.60 on 2025-10-23, establishing a substantial new position worth $1,260,417.07 in a company with zero quarterly revenue and a full-year net loss of $-6,692,000. The purchase occurred at a significant discount to both the current trading price of $1.78 (68% discount to current levels) and well below the 52-week high of $2.85, but notably the stock has experienced a 30-day rally of +270.8% before this filing, suggesting the transaction may not represent an entry point at depressed levels. For an unprofitable clinical-stage biotech, the outsized accumulation by a director warrants scrutiny into whether this reflects confidence in pending developments (trials, partnerships, regulatory progress) or other material nonpublic information not yet disclosed in SEC filings.